Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA. Based on a literature review of clinical trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol. Additionally, diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped. The use of diacerein is associated with common gastrointestinal disorders such as soft stools and diarrhoea, common mild skin reactions, and, uncommonly, hepatobiliary disorders. However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions. Therefore, the ESCEO concludes that the benefit-risk balance of diacerein remains positive in the symptomatic treatment of hip and knee osteoarthritis. Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated.

• MeSH
• anthrachinony farmakologie   MeSH
• antiflogistika farmakologie   MeSH
• farmakovigilance MeSH
• hodnocení rizik MeSH
• léky s prodlouženým účinkem farmakologie   MeSH
• lidé MeSH
• osteoartróza * farmakoterapie   patofyziologie   MeSH
• remodelace kosti účinky léků   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

The aim of this study was to calculate rates of hospitalization for hip fracture and the incidence of hip fractures in the Czech Republic over a period of 29 years. A second aim was to use the most recent data to populate a FRAX(®) model for the assessment of fracture probability in individual patients. Data on hospitalizations for hip fracture (1981-2009) and number of women and men with hip fractures (2000-2009) were obtained, and incidences were computed for the entire population ≥50 years of age. Incidence of hospitalization for hip fracture in the Czech population aged ≥50 years increased progressively by calendar year. Age-standardized incidence of hip fractures increased to 2004 but leveled off thereafter and decreased after 2005. Data for hip fracture risk in 2008 and 2009 and the death hazard were used to populate a Czech-specific FRAX model for the computation of 10-year fracture probability. The customized FRAX model, using the verified epidemiological data, will be used to identify patients at increased fracture risk.

• MeSH
• fraktury kyčle epidemiologie   etiologie   MeSH
• kostní denzita fyziologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• osteoporóza komplikace   epidemiologie   MeSH
• rizikové faktory MeSH
• senioři MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Česká republika MeSH

• Publikační typ
• abstrakty MeSH

• MeSH
• osteoporóza diagnóza   terapie   MeSH

• Publikační typ
• abstrakty MeSH

• MeSH
• biologické markery MeSH
• osteoporóza diagnóza   MeSH
• prognóza MeSH

• MeSH
• nemoci kostí metabolismus   MeSH
• osteoporóza MeSH
• Publikační typ
• monografie MeSH

• Konspekt
• Ortopedie. Chirurgie. Oftalmologie
• NLK Obory
• ortopedie

• Publikační typ
• učebnice MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• revmatologie

• MeSH
• chronické selhání ledvin MeSH
• minerálová a kostní nemoc při chronickém onemocnění ledvin etiologie   MeSH
• vápník metabolismus   MeSH
• vitamin D metabolismus   MeSH
• Publikační typ
• kongresy MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• nefrologie
• urologie

• MeSH
• bisfosfonáty MeSH
• hypertyreóza patofyziologie   MeSH
• imunologické faktory MeSH
• kosti a kostní tkáň patofyziologie   metabolismus   MeSH
• metabolické nemoci kostí farmakoterapie   MeSH
• Publikační typ
• sborníky MeSH

• Konspekt
• Fyziologie člověka a srovnávací fyziologie
• NLK Obory
• vnitřní lékařství
• endokrinologie